Bathi operasional EBITDA: dermatarx.com (DRMA)

Dermata Therapeutics (DRMA) is implementing advanced acne treatments utilizing micronized silica. The EBITDA metric visualizes current cash efficiency, with the value holding at 0.00. Growth is supported by the robotization of laboratory drug mixing and a streamlined import of raw materials from freshwater sponges, ensuring the stability of US research.

This indicator measures net cash flow from operating activities before depreciation and amortization, allowing investors to determine the business's actual ability to generate cash through the EBITDA_Co assessment. For Dermata Therapeutics (DRMA), this metric reflects cost management efficiency, as the absence of proprietary manufacturing plants and the outsourcing of clinical trials minimize capital expenditures, directly impacting the final operating profit.